Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?
12:36pm, Monday, 24'th Feb 2025
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was over.
Eli Lilly's Breakout Is Nearly Here: Performance Metrics/Bullish Support Remain Robust
09:00am, Sunday, 23'rd Feb 2025
LLY's stock is attractively valued with high double digits capital appreciation prospects, driven by its promising GLP-1 therapies/ pipelines. Combined with the growing capacities and double digits gr
3 Magnificent Growth Stocks to Buy Right Now
05:47am, Saturday, 22'nd Feb 2025
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy increase in value.
This Growth Stock Surged 63% in 2024. Here's Why 2025 Could Bring An Even Bigger Gain.
12:47pm, Friday, 21'st Feb 2025
The big pharma sector is one that's generally fallen out of favor for many investors over the past few decades, as large healthcare companies have seen slower growth and consolidation hasn't generally
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:05am, Friday, 21'st Feb 2025
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Grok 3 makes ideal stock portfolio for 2025
07:59am, Friday, 21'st Feb 2025
Artificial intelligence (AI) platforms have been enjoying the spotlight since the original release of ChatGPT in late 2022 and have started gaining increasing traction among investors for apparently o
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile
12:50pm, Thursday, 20'th Feb 2025
Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial stat
Don't Overlook Lilly (LLY) International Revenue Trends While Assessing the Stock
10:15am, Thursday, 20'th Feb 2025
Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Lilly's Chief Scientific Officer: 'We have an obligation to go after big problems'
09:12am, Thursday, 20'th Feb 2025
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.
Lilly's Chief Scientific Officer has big plans for the next generation of weight loss drugs
09:08am, Thursday, 20'th Feb 2025
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.
Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfall
08:50am, Thursday, 20'th Feb 2025
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are transforming the company. Lilly now has an obligation to take on other challenging diseases like Alzheimer's, ALS and chronic pain, said the the compa
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
08:48am, Thursday, 20'th Feb 2025
Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more potent
Digging Into What Hershey and Eli Lilly Told Investors
09:22am, Wednesday, 19'th Feb 2025
In this podcast, Motley Fool analyst Bill Barker and host Ricky Mulvey discuss:
Lilly to participate in TD Cowen's 45th Annual Health Care Conference
10:00am, Tuesday, 18'th Feb 2025
INDIANAPOLIS , Feb. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive vice pres
3 Stocks That Could Trounce the Market in 2025
04:32am, Monday, 17'th Feb 2025
If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.
